Table 4.
Site | Proposed SWS cut-off (m/s) | Sensitivity (%) | Specificity (%) | Correctly classified (%) |
---|---|---|---|---|
A. Healthy controls vs. ARPKD participants | ||||
Liver left lobe | 1.56 | 92 | 96 | 94 |
Liver right lobe | 1.49 | 84 | 88 | 86 |
Spleen | 2.83 | 84 | 83 | 84 |
B. Healthy controls vs. ARPKD participants without portal hypertension | ||||
Liver left lobe | 1.56 | 91 | 96 | 94 |
Liver right lobe | 1.49 | 73 | 83 | 83 |
Spleen | 2.83 | 73 | 83 | 80 |
C. ARPKD participants without vs. with splenomegaly | ||||
Liver left lobe | 2.06 | 86 | 91 | 88 |
Liver right lobe | 1.86 | 86 | 64 | 76 |
Spleen | 3.08 | 79 | 73 | 76 |
D. ARPKD participants without vs. with low platelet counts | ||||
Liver left lobe | 2.37 | 89 | 88 | 88 |
Liver right lobe | 2.52 | 67 | 100 | 88 |
Spleen | 3.60 | 56 | 94 | 80 |
E. ARPKD participants without vs. with definitive portal hypertension | ||||
Liver left lobe | 2.06 | 100 | 91 | 95 |
Liver right lobe | 2.52 | 67 | 100 | 85 |
Spleen | 3.08 | 100 | 73 | 85 |